dc.contributor.author | Paknahad, Zamzam | |
dc.contributor.author | Moravejolahkami, Amir Reza | |
dc.date.accessioned | 2021-03-19T12:49:26Z | |
dc.date.available | 2021-03-19T12:49:26Z | |
dc.date.issued | 2020-09-17 | |
dc.identifier.uri | https://www.eurekaselect.com/185987/article | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/2530 | |
dc.description.abstract | Background: Probiotics can improve immune function for prevention and management of viral infections like SARS-CoV-2 infection (COVID-19 disease).
Methods: We searched on PubMed, EMBASE, Google Scholar, Science Direct, Scopus, and Web of Science up to May 2020 to identify interventional & observational studies documenting the effects of probiotics on incidence, severity, duration, and other clinical manifestations of viral infections especially SARS-CoV-2-induced.
Results: From a total of 91 records, 24 studies were obtained and classified into three domains based on the efficacy of probiotics on 1) shortening the period and severity of infections (n=9), 2) incidence (n=6), and 3) Other clinical complications that may be followed by viral disorders (n=9). Identified probiotics have positive effects on the mentioned domains.
Conclusion: Based on the evidence, some probiotic strains may be useful in SARS-CoV-2 infection; randomized trials are needed to show the facts. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Severe Acute Respiratory Syndrome | en_US |
dc.subject | Virus Diseases | en_US |
dc.subject | Immunity | en_US |
dc.subject | Mycobiome | en_US |
dc.subject | Probiotics | en_US |
dc.subject | Systematic Review | en_US |
dc.title | Probiotics against viruses; COVID-19 is a paper tiger: A Systematic Review | en_US |
eihealth.country | Others | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Slow Spread / Reducir la Dispersión | en_US |
dc.relation.ispartofjournal | Endocr Metab Immune Disord Drug Targets | en_US |